Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib
Status:
Active, not recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving rituximab, lenalidomide, and ibrutinib with
chemotherapy works in treating patients with high-risk diffuse large B-cell lymphoma.
High-risk large B-cell lymphoma is a type of cancer of the immune system that is usually
fast-growing in the body. Monoclonal antibodies, such as rituximab, may block cancer growth
in different ways by targeting certain cells. Ibrutinib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth. Biological therapies, such as
lenalidomide, use substances made from living organisms that may stimulate or suppress the
immune system in different ways and stop cancer cells from growing. Drugs used in
chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and
doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving rituximab, ibrutinib, and lenalidomide with combination chemotherapy may kill more
cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Celgene Janssen Scientific Affairs, LLC National Cancer Institute (NCI)